Evogene (EVGN) Set to Announce Quarterly Earnings on Thursday

Evogene (NASDAQ:EVGN) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 21st. Parties interested in registering for the company’s conference call can do so using this link.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The business had revenue of $0.91 million for the quarter. Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%.

Evogene Price Performance

EVGN opened at $1.88 on Thursday. The company has a market capitalization of $10.10 million, a price-to-earnings ratio of -0.47 and a beta of 1.43. Evogene has a 1-year low of $1.70 and a 1-year high of $10.40. The business has a 50 day moving average price of $2.54 and a two-hundred day moving average price of $4.68.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. StockNews.com assumed coverage on Evogene in a research report on Sunday. They issued a “sell” rating for the company. Lake Street Capital cut their target price on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.